Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881349 | 0.84 | SIRT2 (0.48) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL29203245 | 0.84 | SIRT2 (0.48) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL10139260 | 0.84 | SIRT2 (0.51) | SIRT2SIRT1CYP1A2GRIA1GRIA2 | |
| SCHEMBL29203248 | 0.84 | SIRT2 (0.48) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL30349795 | 0.81 | CYP1A2 (0.60) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL31520802 | 0.78 | SIRT2 (0.50) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL9725457 | 0.76 | SIRT2 (0.51) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL21669286 | 0.76 | MEN1 (0.61) | CYP1A2ALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL9725396 | 0.75 | SIRT2 (0.53) | SIRT2SIRT1CA12CA9CYP1A2 | |
| SCHEMBL24993891 | 0.74 | SIRT2 (0.52) | SIRT2SIRT1CA12CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | SIRT2 1520/4885SIRT1 965/4885CA12 4633/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | SIRT2 1520/4885SIRT1 965/4885CA12 4633/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | SIRT2 1520/4885SIRT1 965/4885CA12 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.